3.5.1.26: N4-(beta-N-acetylglucosaminyl)-L-asparaginase
This is an abbreviated version!
For detailed information about N4-(beta-N-acetylglucosaminyl)-L-asparaginase, go to the full flat file.
Word Map on EC 3.5.1.26
-
3.5.1.26
-
lysosomal
-
aspartylglucosaminuria
-
lepidoptera
-
mitogenome
-
protein-coding
-
microsatellite-like
-
attta
-
poly-a
-
butterfly
-
a+t-rich
-
glycoasparagines
-
nymphalidae
-
aspartylglucosamine
-
dihydrouridine
-
trnaseragn
-
autoproteolysis
-
meningosepticum
-
hesperiidae
-
papilionidae
-
lrrna
-
pieridae
-
non-finnish
-
glcnac-asn
-
clover-leaf
-
medicine
-
lycaenidae
-
trnamet
-
diagnostics
- 3.5.1.26
- lysosomal
- aspartylglucosaminuria
- lepidoptera
-
mitogenome
-
protein-coding
-
microsatellite-like
-
attta
- poly-a
- butterfly
-
a+t-rich
- glycoasparagines
- nymphalidae
- aspartylglucosamine
- dihydrouridine
-
trnaseragn
-
autoproteolysis
- meningosepticum
- hesperiidae
- papilionidae
-
lrrna
- pieridae
-
non-finnish
- glcnac-asn
-
clover-leaf
- medicine
- lycaenidae
- trnamet
- diagnostics
Reaction
Synonyms
1-aspartamido-beta-N-acetylglucosamine amidohydrolase, 4-L-aspartylglucosylamine amido hydrolase, AGA, amidase-1, amidase-2, amidase-3, aspartylglucosaminidase, aspartylglucosylaminase, aspartylglucosylamine deaspartylase, aspartylglycosylamine amidohydrolase, AtAGA, beta-aspartylglucosylamine amidohydrolase, EC 3.5.1.37, GA, glucosylamidase, glycoasparaginase, glycosylasparaginase, LhAGA, More, N-aspartyl-beta-glucosaminidase, N4-(N-acetyl-beta-glucosaminyl)-L-asparagine amidase
ECTree
Advanced search results
Application
Application on EC 3.5.1.26 - N4-(beta-N-acetylglucosaminyl)-L-asparaginase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
diagnostics
medicine
-
elevation of plasma aspartylglucosaminidase is a useful marker for the congenital disorders of glycosylation type I, CDG I
-
fluorometric assay in blood samples allows specific detection of the enzyme defect in aspartylglycosaminuria patients
medicine
deficient AGA activity results in a lysosomal storage disease, aspartylglucosaminuria, resulting in progressive neurodegeneration, most of disease-causing mutations lead to defective molecular maturation of AGA
medicine
-
enzyme deficiency or its absence gives rise to aspartylglycosaminuria, an autosomal recessive inherited disorder that results in the accumulation of glycoasparagines in lysosomes, most common disorder of glycoprotein metabolism
medicine
-
enzyme deficiency or its absence gives rise to aspartylglycosaminuria, the most common disorder of glycoprotein metabolism
medicine
-
a high dose enzyme replacement therapy with glycosylasparaginase in newborn aspartylglycosaminuria mice is up to 2fold more effective in reducing the amount of the accumulated storage material from the brain tissue than enzyme replacement therapy in adult aspartylglycosaminuria animals
medicine
-
human glycosylasparaginase is a potential anticancer agent to induce apoptosis in L-asparagine-dependent cancer cells
medicine
use of codon-optimized AGA may be beneficial for the therapy options in treatment of the lysosomal storage disorder aspartylglucosaminuria (AGU)